

CITATION REPORT

List of articles citing

COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia

DOI: 10.1002/cpt.2117

Clinical Pharmacology and Therapeutics, 2021, 109, 688-696.

Source: <https://exaly.com/paper-pdf/77901463/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
34	Nucleocapsid and Spike Proteins of the Coronavirus SARS-CoV-2 Induce in Monocytes and Macrophages-Potential Implications for Cytokine Storm Syndrome. <i>Vaccines</i> , 2021 , 9,	5.3	18
33	The systemic inflammatory response and clinicopathological characteristics in patients admitted to hospital with COVID-19 infection: Comparison of 2 consecutive cohorts.		
32	Anti-Inflammation, Immunomodulation and Therapeutic Repair in Current Clinical Trials for the Management of COVID-19. <i>Drug Design, Development and Therapy</i> , 2021 , 15, 1345-1356	4.4	
31	Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications. <i>Nature Communications</i> , 2021 , 12, 1618	17.4	46
30	Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 499-511	5.1	12
29	Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials. <i>Intensive Care Medicine</i> , 2021 , 47, 641-652	14.5	22
28	The systemic inflammatory response and clinicopathological characteristics in patients admitted to hospital with COVID-19 infection: Comparison of 2 consecutive cohorts. <i>PLoS ONE</i> , 2021 , 16, e0251924	3.7	6
27	Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. <i>Cells</i> , 2021 , 10,	7.9	2
26	The signal pathways and treatment of cytokine storm in COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 255	21	84
25	Defining Potential Therapeutic Targets in Coronavirus Disease 2019: A Cross-Sectional Analysis of a Single-Center Cohort. 2021 , 3, e0488		0
24	Pharmacokinetic /Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19.		
23	Mast cells: Therapeutic targets for COVID-19 and beyond. <i>IUBMB Life</i> , 2021 , 73, 1278-1292	4.7	4
22	COVID-19 Antiviral and Treatment Candidates: Current Status. <i>Immune Network</i> , 2021 , 21, e7	6.1	5
21	An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).. <i>International Immunopharmacology</i> , 2022 , 105, 108536	5.8	4
20	Therapeutic role of immunomodulators during the COVID-19 pandemic - a narrative review.. <i>Postgraduate Medicine</i> , 2022 ,	3.7	2
19	Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study.. <i>The Lancet Regional Health Americas</i> , 2022 , 100228		
18	Secondary Infection Risk in Patients With Severe COVID-19 Pneumonia Treated With Tocilizumab.. <i>American Journal of Therapeutics</i> , 2022 ,	1	0

17	Potential plants for inflammatory dysfunction in the SARS-CoV-2 infection.. <i>Inflammopharmacology</i> , 2022 , 1	5.1	
16	Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19. <i>Clinical Pharmacokinetics</i> , 2021 , 61, 155	6.2	4
15	Safety and Efficacy of Tocilizumab 4 or 8mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial.. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofab608	1	2
14	Immune-based Therapeutic Approaches in COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2022 , 113107	7.5	0
13	Chlorpromazine, a Clinically Approved Drug, Inhibits SARS-CoV-2 Nucleocapsid-Mediated Induction of IL-6 in Human Monocytes. <i>Molecules</i> , 2022 , 27, 3651	4.8	0
12	Insights from a Rapidly Implemented COVID-19 Biobank Using Electronic Consent and Informatics Tools. <i>Biopreservation and Biobanking</i> ,	2.1	
11	The hormetic and hermetic role of IL-6. <i>Ageing Research Reviews</i> , 2022 , 101697	12	1
10	Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy. 2022 , 23, 7937		
9	Coagulopathy in COVID-19 and anticoagulation clinical trials. 2022 , 101377		1
8	Monoclonal Antibodies: A Therapeutic Option for the Treatment of Ophthalmic Diseases of the Eye Posterior Segment. 2022 , 5, 229-246		0
7	Dose optimisation and scarce resource allocation: two sides of the same coin. 2022 , 12, e063436		0
6	Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?.		0
5	Clinical trials for accelerating pandemic vaccines. 2022 , 38, 797-817		2
4	COVID-19: Inpatient Management. 2023 , 182-232		0
3	Low dose vs high dose tocilizumab in COVID-19 patients with hypoxemic respiratory failure. 2023 , 76, 154291		0
2	A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages. 2023 , 129, 57-62		0
1	An overview on the treatments and prevention against COVID-19. 2023 , 20,		0